SCHEMBL13316484

SCHEMBL13316484

COCCOc1cc(Cl)ncn1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PLAU P00749 1/20 0.36
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDR P35968 7/20 0.34
EGFR P00533 2/20 0.34
FLT1 P17948 2/20 0.33
KDM1A O60341 2/20 0.33
BRAF P15056 1/20 0.33
ELOVL1 Q9BW60 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
FGFR1 P11362 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22576164 0.91 HDAC1 (0.34) ALDH1A1SMN1; SMN2BRAFELOVL1HDAC1
SCHEMBL13316481 0.91 BRAF (0.34) ALDH1A1SMN1; SMN2BRAFELOVL1HDAC1
SCHEMBL14376107 0.82 ENPP1 (0.41) ALDH1A1ELOVL1HDAC1HDAC6HDAC5
SCHEMBL22576224 0.81 NCF1 (0.36) ALDH1A1L3MBTL1ELOVL1HDAC1HDAC6
SCHEMBL22576348 0.80 HPGD (0.34) POLBL3MBTL1ELOVL1HDAC1HDAC6
SCHEMBL15114888 0.78 TSHR (0.36) ALDH1A1SMN1; SMN2EGFRKDM1AELOVL1
SCHEMBL7486936 0.78 THRB (0.38) ALDH1A1ELOVL1HDAC1HDAC6HDAC5
SCHEMBL15933168 0.78 HDAC1 (0.36) ELOVL1HDAC1HDAC6HDAC5
SCHEMBL5386945 0.78 HDAC1 (0.34) ELOVL1HDAC1HDAC6HDAC5
SCHEMBL14387902 0.78 ALDH1A1 (0.39) ALDH1A1HDAC1HDAC6HDAC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 US disclosed
EP-4554938-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 EP disclosed
CN-119894879-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-25 CN disclosed
WO-2024015497-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2024-01-18 WO disclosed
US-20100160311-A1 Fungicidal Azolopyrimidines, Process for Their Preparation and Their Use For Controlling Harmful Fungi, and Also Compositions Comprising Them BASF SE (DE) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160311-A1 Fungicidal Azolopyrimidines, Process for Their Preparation and Their Use For Controlling Harmful Fungi, and Also Compositions Comprising Them G6PD, CYP51A1, ERG28 ALDH1A1 912/4885SMN1; SMN2 4432/4885PLAU 4642/4885
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 ALDH1A1 2989/4885SMN1; SMN2 1972/4885PLAU 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.